Archive: Company News
Company News: Curetis Receives USPTO Notice of Allowance for Key Patent Covering Unyvero Technology
— IP position strengthened in the U.S.
— Patent supports utility of Unyvero Lysator Technology for sample preparation
Curetis N.V. (the “Company” and, together with Curetis USA Inc. and Curetis GmbH, “Curetis“), a developer of next-level molecular diagnostic solutions, today announced that it has received a notice of allowance from the United States Patent & Trademark Office (USPTO) for U.S. Patent Application 14/232,391 (“Apparatus and Method for a Lysis of a Sample, in Particular for an Automated and/or Controlled Lysis of a Sample”) covering its Unyvero Lysator patient sample preparation technology.
Company News: Curetis subsidiary Ares Genetics wins incubator stay in Silicon Valley
— Award winner in “GoSiliconValley” competition by Austrian Economic Chambers
— Support for business development in U.S. market
Curetis N.V. (the “Company” and, together with Curetis USA Inc. and Curetis GmbH, “Curetis“), a developer of next-level molecular diagnostic solutions, today announced that its wholly-owned subsidiary Ares Genetics GmbH (Vienna, Austria) has been selected as a winner of the “GoSiliconValley” competition of the Austrian Economic Chambers (WKO).
Company News: ISA Pharmaceuticals and Scancell enter collaboration agreement for the manufacturing, development and commercialisation of Modi-1 / AMPLIVANT® combination
— AMPLIVANT-Modi-1 conjugate expected to enter clinic in H1 2019
— Collaboration seeks to further leverage Moditope® platform
ISA Pharmaceuticals B.V. (‘ISA’), a clinical-stage immunotherapy company, and Scancell Holdings plc, (‘Scancell’ or the ‘Company’), the developer of novel immunotherapies for the treatment of cancer, are pleased to announce that they have entered into a worldwide licensing and collaboration agreement to use ISA’s AMPLIVANT® adjuvant technology for the manufacturing, development and commercialisation of Scancell’s first Moditope® development candidate, Modi-1.
Company News: TRON receives three-year research grant from the Falconwood Foundation to develop new treatment approaches for neuroendocrine tumors
TRON (Translational Oncology at the University Medical Center of the Johannes Gutenberg University Mainz, Germany), an internationally recognized leader in tumor immunology and cancer therapy research, has announced a three-year grant from the Falconwood Foundation, New York, USA, totalling 3 Million Euros. The grant supports the launch of a new research project to identify biomarkers specific for neuroendocrine tumors (NETs) that are crucial for the development of new, personalized immunotherapies to treat NET patients.